These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 30152872)
1. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis. Green JR; Allison KM; Cordella C; Richburg BD; Pattee GL; Berry JD; Macklin EA; Pioro EP; Smith RA Br J Clin Pharmacol; 2018 Dec; 84(12):2849-2856. PubMed ID: 30152872 [TBL] [Abstract][Full Text] [Related]
2. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Smith R; Pioro E; Myers K; Sirdofsky M; Goslin K; Meekins G; Yu H; Wymer J; Cudkowicz M; Macklin EA; Schoenfeld D; Pattee G Neurotherapeutics; 2017 Jul; 14(3):762-772. PubMed ID: 28070747 [TBL] [Abstract][Full Text] [Related]
3. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999 [TBL] [Abstract][Full Text] [Related]
4. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis. Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979 [TBL] [Abstract][Full Text] [Related]
5. Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis. Tabor Gray L; Locatelli E; Vasilopoulos T; Wymer J; Plowman EK Ann Clin Transl Neurol; 2023 Aug; 10(8):1296-1304. PubMed ID: 37265174 [TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A; Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036 [TBL] [Abstract][Full Text] [Related]
7. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA; Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150 [TBL] [Abstract][Full Text] [Related]
8. Dextromethorphan/quinidine for the treatment of pseudobulbar affect. Patatanian E; Casselman J Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895 [TBL] [Abstract][Full Text] [Related]
9. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507 [TBL] [Abstract][Full Text] [Related]
14. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. Fralick M; Sacks CA; Kesselheim AS JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021 [TBL] [Abstract][Full Text] [Related]
15. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale). Smith RA; Macklin EA; Myers KJ; Pattee GL; Goslin KL; Meekins GD; Green JR; Shefner JM; Pioro EP Eur J Neurol; 2018 Jul; 25(7):907-e66. PubMed ID: 29577526 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic utility of patient-report and speech-language pathologists' ratings for detecting the early onset of bulbar symptoms due to ALS. Allison KM; Yunusova Y; Campbell TF; Wang J; Berry JD; Green JR Amyotroph Lateral Scler Frontotemporal Degener; 2017 Aug; 18(5-6):358-366. PubMed ID: 28355886 [TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. Hammond FM; Sauve W; Ledon F; Davis C; Formella AE PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412 [TBL] [Abstract][Full Text] [Related]
19. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Yang LP; Deeks ED Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446 [TBL] [Abstract][Full Text] [Related]
20. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Thisted RA; Klaff L; Schwartz SL; Wymer JP; Culligan NW; Gerard G; Pope LE; Berg JE Clin Ther; 2006 Oct; 28(10):1607-18. PubMed ID: 17157116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]